Helicobacter Pylori and Steps for its Elimination: A Review

By Sangita Boro & Manash Pratim Sarma
Assam Down Town University

Abstract- The only host for H. pylori is human and it is found to be present in stomach, duodenum, oesophagus and rectum. H. pylorus is responsible for causing chronic infections and therefore its complete eradication from the society is very much essential. This article therefore aims to review the recent treatment options prevalent for the eradication of this dreadful disease.

Keywords: helicobacter pylori, antimicrobial resistance, eradication, therapy.

GJMR-F Classification : NLMC Code: WI 387

Strictly as per the compliance and regulations of:
Helicobacter Pylori and Steps for its Elimination: A Review

Sangita Boro a & Manash Pratim Sarma a

Abstract- The only host for H. pylori is human and it is found to be present in stomach, duodenum, oesophagus and rectum. H. pylorus is responsible for causing chronic infections and therefore its complete eradication from the society is very much essential. This article therefore aims to review the recent treatment options prevalent for the eradication of this dreadful disease.

Keywords: helicobacter pylori, antimicrobial resistance, eradication, therapy.

I. Introduction

Helicobacter pylorus (H. pylori) is a microbial species that specifically colonizes the gastric epithelium. Helicobacter pylori, is a gram-negative, spiral bacterium situated on the epithelial surface of the stomach. It is thought to be the most common bacterial infection worldwide. Virtually, all persons infected by this organism develop gastritis, a signature feature of which is the capacity to persist for decades leading to chronic inflammation of the underlying mucosa. It has been recognized to be associated with increased risk of chronic gastritis, peptic ulcer disease (PUD) (gastric and duodenal), gastric mucosal-associated lymphoid tissue (MALT) lymphoma, gastric adenocarcinoma, World Health Organisation (WHO) has described H. pylori as a class 1 carcinogen for gastric carcinoma. H. pylori infection also induces insulin resistance and has been defined as a predisposing factor to T2D development. Gastric and fecal microbiota may have been changed in H. pylori-infected persons and mice to promote gastric inflammation and specific diseases [1].

Figure 1: A pictorial representation of the diseases involving H. pylori

Source: The Mechanisms of Action and Resistance to Fluoroquinolone in Helicobacter pylori Infection, Carolina Negrei and Daniel Boda, INTECH. 13; 349-378

Authors: a Department of Microbiology, Assam down town University, Panikhaiti, Guwahati, Assam, India.
Authors: a Department of Biotechnology, Assam down town University, Panikhaiti, Guwahati, Assam, India. e-mail: manash3268@gmail.com
Although the incidence varies by geographic location and socioeconomic conditions, *H. pylori* remains one of the most common bacterial infections in the world [2]. Therefore this review aims to find the most prevalent treatment options throughout the world in order to eliminate *H. pylori*.

## II. Antimicrobial Resistance

The main reason behind failure of treatment is antibiotic resistance. The prevalence of antimicrobial resistance has been found to have regional variance both within countries and outside countries. Studies done in India found that drug resistance in *H. pylori* was more for metronidazole, tinidazole and clarithromycin [36]. Clarithromycin resistance was also found to be prevalent in many western countries like USA, Canada, Northern, Southern and Eastern Europe [4]. The high prevalence of resistance in the developing countries compared to the industrialised countries is the high rate of antibiotic misuse. Metronidazole is more commonly used in developing countries for the treatment of parasitic infections whereas in developed countries it is more frequently used for dental and gynaecological infections (53). Patients who had had a failed case of *H. pylori* eradication have been found to be more prone to multi-resistant *H. pylori* than untreated cases [65].

### a) Diagnosis

The diagnostic tests for *H. pylori* infection include endoscopic and non-endoscopic methods. The techniques used may be direct (culture, microscopic demonstration of the organism) or indirect (using urease, stool antigen or an antibody response as a marker of disease). The choice of test depend on factors like the cost and the requirement of the test i.e. whether it is for establishing the diagnosis of infection or for the eradication of the disease [7]. Successful eradication should always be confirmed by urea breath test (UBT) or an endoscopy based test. If UBT is not available then Stool Antigen Test (SAT) should be the alternative [8].

### b) Treatment

![Flowchart of the prevailing treatment regime](http://www.clinsci.org/content/110330)

#### First-line treatment

- Amoxicillin + clarithromycin + PPI
- Metronidazole + clarithromycin + PPI

No further treatment

#### Second-line treatment

- Metronidazole + tetracycline + PPI + bismuth

No further treatment

#### Third-line treatment

- Antibiotic susceptibility testing

### c) Sequential Therapy

Since there has been tremendous decline in the cure rate of *H. pylori* hence sequential therapy was introduced. The sequential therapy in which PPI plus amoxicillin are given for 5 days followed by PPI plus clarithromycin and tinidazole also for 5 days has been found to have eradication rates close to or greater than 90%. In a number of Italian studies this sequential therapy has proved to be superior than the standard triple therapy in eradicating both susceptible and resistant *H. pylori* strains [8]. The incidence of side-effects was similar with both regimes in these trials. This treatment regimen appeared to overcome clarithromycin resistance. [9]

### d) First Line Treatment

For over a decade the proton pump inhibitor (PPI)-based triple therapy has been used as the first line treatment of choice [10]. The currently approved regimen i.e. (a triple therapy consisting of a proton pump inhibitor, amoxicillin and clarithromycin) has been recommended by the European Helicobacter Study Group [11]. The currently approved regimen now been proven to be relatively ineffective because of the high
rate of clarithromycin resistance [12-16]. In many countries this therapy has been considered to be obsolete but since this is the only approved therapy by the government insurance the doctors are still in a dilemma. In the United States four drugs combinations therapy has been used (e.g., 14 day therapy with a proton pump inhibitor, clarithromycin, metronidazole, and amoxicillin or concomitant therapy which is effective except in the presence of clarithromycin-metronidazole dual resistance) or the combination of a bismuth, tetracycline, metronidazole and a proton pump inhibitor which is generally effective despite metronidazole resistance provided it is given a full dose and for 14 days [17, 18]. The combination of a high dose proton pump inhibitor and amoxicillin such as 20 mg of rabeprazole and 500 to 750 mg of amoxicillin every 6 hours for 14 days appears to be effective in Asia [19]. No single therapy can be recommended for any area as there are wide variations in the resistance patterns in different parts of the world.

Factors influencing outcome:

<table>
<thead>
<tr>
<th>Treatment:</th>
<th>Strains:</th>
<th>Patients:</th>
</tr>
</thead>
<tbody>
<tr>
<td>Increasing the dose of clarithromycin to 1-1.5 mg per day improves cure rates</td>
<td>Resistance of H. pylori to antimicrobial agents.</td>
<td>Depending on geographical region of patients.</td>
</tr>
<tr>
<td>The optimal duration of treatment has been found that better cure rates have been found for longer treatment duration.</td>
<td>Strain type.</td>
<td>Patient compliance.</td>
</tr>
</tbody>
</table>

Since so many factors has to be considered, therefore it is very essential to have an organized program to identify the resistance pattern in order to define highly effective regimes.

e) Quadruple

Bismuth quadruple therapy entails: bismuth 525 mg four times daily, metronidazole 250 mg four times daily, tetracycline 500 mg four times daily and a standard dose PPI for a total of 7-14 days. On seeing there ported eradication rate of 87%, some authors advocate bismuth based quadruple therapy as first line therapy for H. pylori [20-22]. In areas of high clarithromycin resistance (> 15 percent) or in patients with a documented penicillin allergy the clinicians may consider Bismuth based quadruple therapy as first line treatment. [23,24]. The side effect profile of standard triple therapy versus quadruple therapy is almost equivalent as the overall adverse event rate in the quadruple therapy treatment arm was 58.5% compared to 59.0% in the triple therapy arm [25,26]. Symptoms included: diarrhea, dyspepsia, nausea, abdominal pain, and taste perversion, changes in stool colour or firmness and headache.

f) Second-Line Therapy

H. pylori may develop resistance to the prescribed antibiotics used for the first-line therapy. The resistance may be acquired by acquisition and recombination of genes from other bacteria and chromosomal mutations [27, 28]. Clarithromycin and Metronidazole appear to be the two antibiotics noted for resistance and most of H. pylori isolates after two eradication failures are resistant to the two drugs [29]. Subsequently, quadruple therapy which consists of PPI, bismuth, metronidazole and tetracycline is a recommended alternative to first-line treatment, which may be advocated in areas of high antibiotic resistance. In any case if bismuth is not available, second-line therapy may be with PPI-based triple therapy. [10]

g) Third-Line (Rescue/Salvage) Therapy

On multiple (at least two) treatment failures with different regimes the third line therapy is applied. Ideally, it would be chosen based on the results of antimicrobial susceptibility testing. Since it was noted that most of H. pylori isolates after two eradication failures are resistant to metronidazole and clarithromycin therefore, has been recommended to exclude the two drugs from the third-linetherapy. As a result, the third-line therapy is now being applied in some countries. These third-line therapies are the new emerging therapies. [8]
Concomitant Therapy

Concomitant therapy entails: Standard dose PPI, Amoxicillin 1000mg twice daily, Clarithromycin 500mg twice daily and Metronidazole500 mg twice daily for 10-14 days. In terms of eradication it is similar to sequential therapy with an eradication rate of 94% and maybe a simple regimen when compared to sequential therapy as all antibiotics are given once. A randomized trial comparing sequential and concomitant therapy, demonstrated comparable eradication rates (92.3% versus 93%, respectively) and similar adverse event rates (30.7% versus 26.9%). A regimen consisting of: esomeprazole and amoxicillin for seven days then esomeprazole, amoxicillin, clarithromycin, and metronidazole for 7 seven days (sequential-concomitant hybrid therapy) generated a 99.1% eradication rate in 117 patients [2].

Emerging Therapies

i. Levofloxacin based therapies

Levofloxacin-based triple therapies are now becoming the second-line treatment of choice in some European countries. It has proven very effective in the treatment of H. pylori infection in a study carried out in Italy. In a comparative study in Italy, the eradication rate achieved with levofloxacin-based triple therapy as a first-line treatment was significantly higher than that with standard therapies. Levofloxacin has been advocated for use in second- and third-line “rescue” regimens. Levofloxacin may thus represent a reasonable treatment regimen in the setting of Clarithromycin resistance [8].

ii. Lactoferrin

Lactoferrin is a natural antibiotic which is found in bovine milk. It has been found to be bacteriostatic to H. pylori both in vivo and in vitro. It is a milk protein that binds iron and its addition to the regular treatment regimen for H. pylori may improve eradication rates. Studies have been carried out to determine its use in combination with PPI and other antibiotics with varying efficacy. This modality of treatment has not been universally accepted [8].

iii. Levofloxacin and rifaximin-based quadruple therapy

Levofloxacin and rifaximin-based quadruple regimen as first-line treatment for H. pylori infection has
been studied by Choi et al. but has limited efficacy in a Korean cohort [30]. Further multi-centred studies may be required in other countries.

III. Conclusion

Despite the introduction of various treatment regimens, *H. pylori* infection is still a major problem of concern. Though the clinicians have many different treatment regimens within them but standard PPI based triple therapy and bismuth based quadruple therapy remain in first line as the eradication rates remain relatively high (70-80%). The increased resistance of drugs and non compliance, due to complexity of regime and associated side effects has led to the investigation of many other therapeutic options which is necessary for the complete eradication of *H. pylori*. Hence from this review we can conclude that further many more trials are necessary to get a complete eradication of *H. pylori*.

IV. Future Treatment Module

The next generation of *H. pylori* therapeutic regimens should be simpler, novel and specific. There are some novel approaches available to achieve this goal, such as-

1) Development of therapeutic vaccine
2) Genome based drug discovery
3) Pathogen –host tissue adhesion inhibitor
4) Novel site specific drug delivery at specific site of *H. pylori* infection.

Although combination therapies have been found to have high rates of eradication, therapies that would be preferred are the ones which use a low dose of single drug with a short duration treatment and without any adverse effect.

**References Références Referencias**


